NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck and Roche for CPI combination trials. Follow us on X @neoimmunetech
Looking for a particular NeoImmuneTech employee's phone or email?
NeoImmuneTech Questions
The NeoImmuneTech annual revenue was $3 million in 2026.
Daniel Rho is the Senior Director Business Development of NeoImmuneTech.
26 people are employed at NeoImmuneTech.
NeoImmuneTech is based in Rockville, Maryland.
The NAICS codes for NeoImmuneTech are [541, 54171, 541714, 5417, 54].
The SIC codes for NeoImmuneTech are [87, 873].
Top NeoImmuneTech Employees
-
Daniel Rho
Senior Director Business Development at NeoImmuneTech
Rockville, MD, US23 -
Alexandra Wolfarth
Lead Scientist at NeoImmuneTech
Rockville, MD, US12 -
11
-
Sun Kim
Statutory Auditor at NeoImmuneTech
Washington, DC, US21 -
지영 주
Executive Director at NeoImmuneTech
Incheon, South Korea -
Wu Janet
Senior Regulatory Affairs Manager at NeoImmuneTech
San Diego, CA, US -
Patrick Price
Business Area Leader at NeoImmuneTech
Houston, TX, US5+5+ -
희영 정
Senior Director of CMC QA at NeoImmuneTech
South Korea1
Related Companies
